Access is tightly limited: enrollees need high BMI scores and certain health conditions, while patients using GLP-1s for diabetes or sleep apnea are excluded and must navigate prescriptions and prior authorizations
More research about this risk is needed
"For the newer GLP-1 medications, it would be useful to look at whether there are genetic variants, like the variants in PAM , that explain poor responders to their medications." "There are a whole class of medications that are insulin sensitizers, so perhaps we can develop medications that will allow people to be sensitized to GLP-1s or find formulations of GLP-1, like the longer-acting versions, that avoid the GLP-1 resistance." The research has been published in Genome Medicine .
A story in The Economic Times with Rica Bhattacharyya Read more here: Interesting development
Ongoing research aims to better understand the varying responses to GLP-1 drugs and identify predictors of treatment success
Topical clindamycin therapy for acne vulgaris
